SWEEP
25.5.2023 00:02:32 CEST | Business Wire | Press release
Sweep, the leading carbon and ESG management platform, today launched Sweep for Compliance, the first solution for reliable, transparent, and audit-ready reporting in compliance with the EU’s new Corporate Sustainability Reporting Directive (CSRD).
By 2025, an estimated 50,000 European Union businesses and at least 10,000 EU-based foreign companies will be falling under the scope of the CSRD, requiring them to communicate their 2024 extra-financial information. Globally, a rising number of sustainability disclosure regulations demand companies and financial institutions to track and publicly communicate new sets of data. If companies fail to act, they face compliance risks, such as financial sanctions, legal penalties, and damaging greenwashing accusations.
But, measuring ESG and carbon data is complex and time consuming without the right technology. Two-thirds (65%) of French business leaders believe their organization is not sufficiently prepared to meet ESG objectives, nor to fulfill regulatory requirements according to Workiva. Sweep for Compliance helps businesses easily comply with the right ESG, carbon, and regulatory disclosure requirements using advanced data analytics and reporting requirements directly embedded into the platform.
“In 2023, data collection can’t be a bottleneck for companies to track and improve their positive impact. Monitoring extra financial data is now a crucial business issue as European sustainability regulations become more stringent. Sweep for Compliance gives CFOs, CSOs, and auditors the most advanced tools to measure carbon and ESG data and comply with upcoming legislation,” says Rachel Delacour, CEO and Cofounder at Sweep.
Sweep for Compliance streamlines the disclosure exercise, from data gathering and quality checks, traceability and monitoring, to generating insights and in-depth reports. With up to 50% time saved in the auditing process, it ensures consistent, verified, and compliant ESG and carbon data reporting in one click. It’s the only solution on the market to help companies get ready and stay on track with disclosure requirements.
“With the growing number of sustainability regulations and stakeholder demands for transparency, companies are under pressure to accurately communicate their impact. By working with tech partners like Sweep, large organizations can streamline the collection, monitoring, and reporting of their non financial data in one single place,” says Jérémie Joos, Co-Head of ESG Center of Excellence at KPMG France.
Sweep is the trusted data partner for companies such as pet food giant Royal Canin and global leader in connected health company Withings. After launching Sweep for Supply Chain in February 2023, the company is committed to creating the best solutions for organizations to improve their ESG and carbon impact while avoiding non-compliance damages. That’s how they can lead – and thrive – in the future low carbon economy.
• • •
About Sweep
Sweep helps businesses track and act on their carbon and ESG data, so they can become Forever Companies.
The data-driven platform makes it easy to understand, manage, and report carbon emissions and ESG metrics. Powerful collaboration features and user-focused design empower staff and entire value chains to grow a sustainable business. And with all the data in one place, its advanced analytics offer comprehensive insights and deliver auditable reports aligned with the latest sustainability regulations and frameworks.
Sweep is B Corp certified and a member of the World Bank’s Carbon Pricing Leadership Coalition, France Invest, and The International Emissions Trading Association. It was selected to join FrenchTech Next 120/40 program and was named “Europe’s fastest growing scale up by Financial Times’ Sifted.
For more information, visit sweep.net
About KPMG France
KPMG in France – market leader in Audit and Consulting – is a 11,000-strong team of professionals dedicated to creating a new prosperity that's set to enhance companies of all sizes. In 2022, a century after its founding, KPMG became a "société à mission” (Purpose-driven company). Its purpose is to work and innovate with passion, to build trust, to combine performance and responsibility and to develop talent at the heart of the economy, territories and society. Thanks to its multidisciplinary model, KPMG combines industry, ESG and digital expertise by relying on its ESG Center of Excellence and its community of 1 000 digital experts to support the growth and transformation projects of its 100,000 clients all over the country.
For more information, visit kpmg.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005716/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom